ELOVL6 and metabolic dysfunction-associated steatohepatitis: Interesting in this context are the recent observations that ELOVL6 promotes inflammation by C18-mediated lipotoxicity and immune interaction in NASH [11, 18, 39], diet-induced insulin resistance [40–42] and atherosclerosis [43].